By Nigam Arora Nigam Arora returns to the Schwab Network and weighs in on Nvidia’s (NVDA) eye-watering rally, the Mag 7’s general outperformance, and why he expects institutional investors to push the market leaders higher into the end of 2025. He sees portfolio managers buying more shares to match stock performance,
By Nigam Arora To gain an edge, this is what you need to know today. Buffett Sells Stocks Please click here for a chart of Warren Buffett’s company Berkshire Hathaway stock (BRK.B). Note the following: The Morning Capsule is about the big picture, not an individual stock. The chart of BRK.B
By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning
By Nigam Arora 245% Gain Guardant Health (GH) is long from $26.34. It is trading at $91.02 as of this writing, representing a 245% gain. Buyout Target GH is a buyout target. Cancer Screening Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how
By Nigam Arora Editor’s note: This post was published yesterday in The Arora Report paid feeds as an Afternoon Capsule. To gain an edge, this is what you need to know now. December Not A Done Deal Please click here for a chart of S&P 500 ETF (SPY) which represents the
By Nigam Arora To gain an edge, this is what you need to know today. Two Nvidia Shockers Please click here for a chart of Nvidia stock (NVDA). Note the following: The Morning Capsule is about the big picture, not an individual stock. The chart of NVDA stock is being used
By Nigam Arora Editor’s note: This signal was published on October 23, 2025, in ZYX Emerging Alert for paid members. Russian Oil Please start out by reading the Morning Capsule published on October 23rd. Here are the key points: India imports 38% of Russia’s oil. India is reportedly getting a 15%
By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases
By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning
By Nigam Arora To gain an edge, this is what you need to know today. Deploy Cash The adaptive ZYX Asset Allocation Model with inputs in ten categories has given a signal to deploy cash. The trigger for this move is cooler than expected Consumer Price Index (CPI). In the Arora